Literature DB >> 12119998

Use of beta-blockers in obesity hypertension: potential role of weight gain.

T Pischon1, A M Sharma.   

Abstract

Beta-blockers are the most frequently used drugs for the treatment of hypertension. Apart from concerns regarding potential adverse metabolic effects on lipids or insulin sensitivity, beta-blockers can also cause weight gain in some patients. This fact appears little known to clinical practitioners and trialists. Thus, only a minority of clinical trials with beta-blockers report weight changes during treatment. In trials that do report weight changes, beta-blockers are associated with a weight gain of 1.2 (range -0.4-3.5) kg. This may be attributable to the fact that beta blockade can decrease metabolic rate by 10%. Beta-blockers may also have other negative effects on energy metabolism. Obesity management in overweight hypertensive patients may therefore be more difficult in the presence of beta-blocker treatment. We therefore question the use of beta-blockers as first-line therapy for overweight or obese patients with uncomplicated hypertension.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12119998     DOI: 10.1046/j.1467-789x.2001.00044.x

Source DB:  PubMed          Journal:  Obes Rev        ISSN: 1467-7881            Impact factor:   9.213


  18 in total

Review 1.  The role of Beta-blockers as first-line therapy in hypertension.

Authors:  Alberto Ranieri De Caterina; Antonio Maria Leone
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

2.  Prevalence and correlates of eating disorder co-morbidity in patients with bipolar disorder.

Authors:  Jennifer E Wildes; Marsha D Marcus; Andrea Fagiolini
Journal:  Psychiatry Res       Date:  2008-09-07       Impact factor: 3.222

3.  Does it matter how we lower blood pressure in obese hypertensive patients?

Authors:  Arya M Sharma
Journal:  Curr Hypertens Rep       Date:  2008-02       Impact factor: 5.369

Review 4.  Metabolic Syndrome in Children and Adolescents: Diagnostic Criteria, Therapeutic Options and Perspectives.

Authors:  Paul Weihe; Susann Weihrauch-Blüher
Journal:  Curr Obes Rep       Date:  2019-12

5.  Changes in lifestyle after hypertension diagnosis in Canada.

Authors:  C Ineke Neutel; Norm R C Campbell
Journal:  Can J Cardiol       Date:  2008-03       Impact factor: 5.223

6.  Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study.

Authors:  Britt Kveiborg; Thomas S Hermann; Atheline Major-Pedersen; Buris Christiansen; Christian Rask-Madsen; Jakob Raunsø; Lars Køber; Christian Torp-Pedersen; Helena Dominguez
Journal:  Cardiovasc Diabetol       Date:  2010-05-25       Impact factor: 9.951

Review 7.  The management of hypertension in the overweight and obese patient: is weight reduction sufficient?

Authors:  James D Douketis; Arya M Sharma
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Obesity in Women: Insights for the Clinician.

Authors:  Zujaja Tauqeer; Gricelda Gomez; Fatima Cody Stanford
Journal:  J Womens Health (Larchmt)       Date:  2017-10-27       Impact factor: 2.681

Review 9.  Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets.

Authors:  Ioannis Akoumianakis; Akansha Tarun; Charalambos Antoniades
Journal:  Br J Pharmacol       Date:  2016-12-14       Impact factor: 8.739

Review 10.  Hypertension--a treatable component of the cardiometabolic syndrome: challenges for the primary care physician.

Authors:  Camila M Manrique; Guido Lastra; John Palmer; Craig S Stump; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.